Glutamate

• USES: • For the temporary relief of symptoms including: • headache • dizziness • mood changes • vomiting • nausea • abdominal cramps • abdominal pain • fatigue • weakness These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.ICD-10: R11.2, R51.9

DIRECTIONS: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.

If pregnant or breastfeeding, ask a health professional before use. Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. Tamper Evident: Sealed for your protection. Do not use if seal is broken or missing.

1. 1Accidental Overdose17.7%
2. 2Arrhythmia17.7%
3. 3Bacterial Tracheitis17.7%
4. 4Brain Death17.7%
5. 5Breast Cancer Female17.7%
6. 6Cardiac Failure17.7%
7. 7Cardio-respiratory Arrest17.7%
8. 8Cardiomyopathy17.7%
9. 9Cardiopulmonary Failure17.7%
10. 10Cardiotoxicity17.7%
11. 11Cerebral Haemorrhage17.7%
12. 12Cerebral Infarction17.7%
13. 13Chest Pain17.7%
14. 14Confusional State17.7%
15. 15Death17.7%

Recent PubMed references pinned to Glutamate as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Electroacupuncture Alleviates Pain and Anxiety in CFA-Induced Mice by Suppressing Glutamatergic Neurons in the Spinoparabrachial Pathway.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 · Ji Y, Ye R, He W, et al.
  PMID 42240472DOI 10.1096/fj.202504511RR
• Method for Individual Assessment of Human Cerebral Cortex Activity by a Combined Use of Magnetic Resonance Spectroscopy of Glutamate and BOLD Signal Method.
  Biochemistry. Biokhimiia · 2026 · Korotkov AD, Myznikov AD, Krasnov IM, et al.
  PMID 42219388DOI 10.1134/S0006297926600213
• Mechanistic insights into pulsed electric field-induced oxidative degradation of arginine and glutamic acid: Combined experimental characterization and DFT computation.
  Food research international (Ottawa, Ont.) · 2026 · Hu X, Jiang Q, Tu Z, et al.
  PMID 42215105DOI 10.1016/j.foodres.2026.119437
• Activity-based anorexia enhances glutamatergic synaptic transmission and neuronal excitability within the nucleus accumbens of female mice.
  Physiological reports · 2026 · Bailey LG, Christensen CW, Weed SE, et al.
  PMID 42210723DOI 10.14814/phy2.70936
• Protonation States of Proton-Sensing Glutamate Residues in Transporter Sialin.
  International journal of molecular sciences · 2026 · Wooten E, Chon NL, Dzhalolov M, et al.
  PMID 42196605DOI 10.3390/ijms27104629
• Multi-Matrix LC-MS/MS Validation of Methotrexate Polyglutamates: Comparison of VAMS, DBS, and Conventional Blood Sampling in Rheumatoid Arthritis.
  International journal of molecular sciences · 2026 · Kocur A, Kajfasz M, Mikulska A, et al.
  PMID 42196403DOI 10.3390/ijms27104429
• In situ biotransformation of synthetic glutamate to γ-amino butyric acid by an auxotrophic Lactococcus lactis in polysorbate-mediated thermoaerobic process.
  Biodegradation · 2026 · Ali S, Arif K, Khan QF, et al.
  PMID 42174258DOI 10.1007/s10532-026-10313-x
• Double-network PVA/γ-PGA/fucoidan hydrogels with favourable biocompatibility and anti-inflammatory activity for wound healing.
  Carbohydrate polymers · 2026 · Li A, Yang J, He Y, et al.
  PMID 42173601DOI 10.1016/j.carbpol.2026.125403

The 10 most recently updated of 1,602 ClinicalTrials.gov registrations naming Glutamate as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
  Recruiting · Phase 2 · Interventional · 130 enrolled · Merck Sharp & Dohme LLC
  NCT07252739updated 2026-06-12
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  Recruiting · Phase 3 · Interventional · 1,210 enrolled · National Cancer Institute (NCI)
  NCT04267848updated 2026-06-12
• Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
  Recruiting · Phase 2 · Interventional · 64 enrolled · Northwestern University
  NCT06630416updated 2026-06-12
• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  Recruiting · Phase 3 · Interventional · 675 enrolled · Merck Sharp & Dohme LLC
  NCT07190248updated 2026-06-12
• Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
  Recruiting · Phase 1 · Phase 2 · Interventional · 252 enrolled · AbbVie
  NCT06772623updated 2026-06-12
• Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
  Recruiting · Phase 2 · Interventional · 60 enrolled · Boehringer Ingelheim
  NCT07486817updated 2026-06-12
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  Recruiting · Phase 1 · Phase 2 · Interventional · 60 enrolled · National Cancer Institute (NCI)
  NCT06694454updated 2026-06-12
• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
  Not yet recruiting · Phase 2 · Phase 3 · Interventional · 90 enrolled · Sichuan Baili Pharmaceutical Co., Ltd.
  NCT07642024updated 2026-06-11
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
  Recruiting · Phase 2 · Interventional · 42 enrolled · National Cancer Institute (NCI)
  NCT05198830updated 2026-06-11
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
  Recruiting · Phase 3 · Interventional · 304 enrolled · National Cancer Institute (NCI)
  NCT06096844updated 2026-06-11

Frequently asked questions

What is Glutamate used for?

According to FDA labeling, Glutamate carries indications including: USES: • For the temporary relief of symptoms including: • headache • dizziness • mood changes • vomiting • nausea • abdominal cramps • abdominal pain • fatigue • weakness These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What are the brand names for Glutamate?

Glutamate is marketed under brand names including Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, Glutamic-500.